ArticleClinical epidemiology2023
Cross-Regional Data Initiative for the Assessment and Development of Treatment for Neurological and Mental Disorders.
Article in Clinical epidemiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- SGLT2 Inhibitors and Asthma Exacerbation Risk Among Patients With Type 2 Diabetes and Asthma: A Target Trial Emulation.Clinical pharmacology and therapeutics · 2026Article
- Emulating Six Cardiovascular Outcome Trials of Antidiabetic Drugs in Individuals with Type 2 Diabetes: Analyses Based on Real-World Databases from Korea and Taiwan.Clinical pharmacology and therapeutics · 2026Article
- Association between venlafaxine use and the risk of withdrawal from nonopioid substances: a nationwide, population-based study.Harm reduction journal · 2026Article
- Association Between Pneumonia Risk and Anticholinergic Burden Among Patients with Different Frailty Levels [Response to Letter].Clinical epidemiology · 2026Article
- SGLT2 Inhibitors and External Genital Infection in Male Patients With Type 2 Diabetes.JAMA network open · 2025Article
- 10 Practical Considerations for the Conduct of Multi-National/Database Studies in Pharmacoepidemiology.Pharmacoepidemiology and drug safety · 2025Review
- Prescription patterns of traditional Chinese medications and potential consequences in patients with new-onset cardiac or vascular-related diseases: a nationwide cohort study.BMC complementary medicine and therapies · 2025Article
- Association between dementia and left atrial appendage occlusion in patients with atrial fibrillation: A TriNetX-based retrospective cohort study with target trial emulation.Heart rhythm O2 · 2025Article
- Epidemiology and Burden of Illness of Lennox-Gastaut Syndrome in Taiwan: A Retrospective Cohort Study.Risk management and healthcare policy · 2025Article
- Taiwan's National Health Insurance Research Database (NHIRD): in the Era of Artificial Intelligence, Causal Inference, and Data Security.Clinical epidemiology · 2025Review
- Perspective review: Will generative AI make common data models obsolete in future analyses of distributed data networks?Therapeutic advances in drug safety · 2025Review
- Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD.JAMA network open · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Funding
Abstract
Purpose: To describe and categorize detailed components of databases in the Neurological and Mental Health Global Epidemiology Network (NeuroGEN). Methods: An online 132-item questionnaire was sent to key researchers and data custodians of NeuroGEN in North America, Europe, Asia and Oceania. From the responses, we assessed data characteristics including population coverage, data follow-up, clinical information, validity of diagnoses, medication use and data latency. We also evaluated the possibility of conversion into a common data model (CDM) to implement a federated network approach. Moreover, we used radar charts to visualize the data capacity assessments, based on different perspectives. Results: The results indicated that the 15 databases covered approximately 320 million individuals, included in 7 nationwide claims databases from Australia, Finland, South Korea, Taiwan and the US, 6 population-based electronic health record databases from Hong Kong, Scotland, Taiwan, the Netherlands and the UK, and 2 biomedical databases from Taiwan and the UK. Conclusion: The 15 databases showed good potential for a federated network approach using a common data model. Our study provided publicly accessible information on these databases for those seeking to employ real-world data to facilitate current assessment and future development of treatments for neurological and mental disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.